Seres Therapeutics FY2025 net income from continuing operations was USD 5.7 million

Reuters03-12

Seres <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY2025 net income from continuing operations was USD 5.7 million

Seres reported FY 2025 net income from continuing operations of USD 5.7 million and total revenue of USD 789,000. FY 2025 R&D expenses fell 24% to USD 49.06 million, driven by lower personnel expenses, lower live biotherapeutics platform investments, and lower SER-155 program expenses. FY 2025 G&A expenses decreased 26% to USD 39.16 million, reflecting reduced personnel expenses, lower professional fees, and lower facility-related costs and cost management activities. Seres ended 2025 with USD 45.77 million in cash and cash equivalents and said it expects to fund operations through Q3 2026. The company said enrollment is complete in an investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis (15 subjects), with clinical data expected in Q2 2026, while SER-155 for preventing serious bloodstream infections in allo-HSCT patients is Phase 2-ready pending funding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603120700PRIMZONEFULLFEED9670560) on March 12, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618136927?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618136927","market":"fut","top_or_hot":-1,"title":"Seres Therapeutics FY2025 net income from continuing operations was USD 5.7 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Seres <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 net income from continuing operations was USD 5.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Seres reported FY 2025 net income from continuing operations of USD 5.7 million and total revenue of USD 789,000. FY 2025 R&amp;D expenses fell 24% to USD 49.06 million, driven by lower personnel expenses, lower live biotherapeutics platform investments, and lower SER-155 program expenses. FY 2025 G&amp;A expenses decreased 26% to USD 39.16 million, reflecting reduced personnel expenses, lower professional fees, and lower facility-related costs and cost management activities. Seres ended 2025 with USD 45.77 million in cash and cash equivalents and said it expects to fund operations through Q3 2026. The company said enrollment is complete in an investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis (15 subjects), with clinical data expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, while SER-155 for preventing serious bloodstream infections in allo-HSCT patients is Phase 2-ready pending funding.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603120700PRIMZONEFULLFEED9670560) on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Seres Therapeutics FY2025 net income from continuing operations was USD 5.7 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSeres Therapeutics FY2025 net income from continuing operations was USD 5.7 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 19:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Seres <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 net income from continuing operations was USD 5.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Seres reported FY 2025 net income from continuing operations of USD 5.7 million and total revenue of USD 789,000. FY 2025 R&amp;D expenses fell 24% to USD 49.06 million, driven by lower personnel expenses, lower live biotherapeutics platform investments, and lower SER-155 program expenses. FY 2025 G&amp;A expenses decreased 26% to USD 39.16 million, reflecting reduced personnel expenses, lower professional fees, and lower facility-related costs and cost management activities. Seres ended 2025 with USD 45.77 million in cash and cash equivalents and said it expects to fund operations through Q3 2026. The company said enrollment is complete in an investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis (15 subjects), with clinical data expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026, while SER-155 for preventing serious bloodstream infections in allo-HSCT patients is Phase 2-ready pending funding.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603120700PRIMZONEFULLFEED9670560) on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL2V3MZ2:1","article_id":"2618136927","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618136927","pubTimestamp":1773313707,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Seres reported FY 2025 net income from continuing operations of USD 5.7 million and total revenue of USD 789,000. FY 2025 R&D expenses fell 24% to USD 49.06 million, driven by lower personnel expenses, lower live biotherapeutics platform investments, and lower SER-155 program expenses. FY 2025 G&A expenses decreased 26% to USD 39.16 million, reflecting reduced personnel expenses, lower professional fees, and lower facility-related costs and cost management activities. Seres ended 2025 with USD 45.77 million in cash and cash equivalents and said it expects to fund operations through Q3 2026. The company said enrollment is complete in an investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis , with clinical data expected in Q2 2026, while SER-155 for preventing serious bloodstream infections in allo-HSCT patients is Phase 2-ready pending funding.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","MCRB":"Seres Therapeutics, Inc.","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技"},"translate_title":"Seres Therapeutics 2025财年持续经营净利润为570万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MCRB":0.9,"NDAQ":0.9},"content_text":"Seres Therapeutics FY2025 net income from continuing operations was USD 5.7 million\n    \n\n        Seres reported FY 2025 net income from continuing operations of USD 5.7 million and total revenue of USD 789,000. FY 2025 R&D expenses fell 24% to USD 49.06 million, driven by lower personnel expenses, lower live biotherapeutics platform investments, and lower SER-155 program expenses. FY 2025 G&A expenses decreased 26% to USD 39.16 million, reflecting reduced personnel expenses, lower professional fees, and lower facility-related costs and cost management activities. Seres ended 2025 with USD 45.77 million in cash and cash equivalents and said it expects to fund operations through Q3 2026. The company said enrollment is complete in an investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis (15 subjects), with clinical data expected in Q2 2026, while SER-155 for preventing serious bloodstream infections in allo-HSCT patients is Phase 2-ready pending funding.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603120700PRIMZONEFULLFEED9670560) on March 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618136927","isCrawlerRequest":true}